Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinso
Phase 3
Recruiting
- Conditions
- Parkinson disease.Secondary parkinsonism, unspecifiedG21.9
- Registration Number
- IRCT20211008052695N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
1) Diagnosis of Parkinson's disease based on examination and history 2) Patients with stage 2-4 of Hoehn and yahr scale; 3) Normal tests (vitamin B12, thyroid, liver, and kidney tests) 4) Levodopa treatment for at least 3 months before the study 5) Ability to walk at least 20 steps without the use of assistive devices
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Freezing of gait in patient with Parkinson. Timepoint: Patients are treated with atomoxetine at a dose of 40 mg for 2 weeks and then increase the dose to 80 mg for six weeks. Method of measurement: The first visit will be on the first day and before starting treatment, determining the FOGQ questionnaire's score, and starting the medication. This questionnaire consists of 6 questions, each of which receives a score of 0 to 4, and the minimum score is 0, and the maximum is 24. The second visit will take place two weeks after the start of treatment, and the third visit will take place 6 weeks after the second visit.
- Secondary Outcome Measures
Name Time Method